Peregrine Capital Management LLC lessened its holdings in shares of GALAPAGOS NV/S (NASDAQ:GLPG) by 0.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,658 shares of the biotechnology company’s stock after selling 569 shares during the quarter. Peregrine Capital Management LLC owned approximately 0.17% of GALAPAGOS NV/S worth $7,950,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in GLPG. AMP Capital Investors Ltd bought a new stake in GALAPAGOS NV/S during the second quarter worth approximately $221,000. Financial Gravity Wealth Inc. boosted its position in GALAPAGOS NV/S by 64.1% during the third quarter. Financial Gravity Wealth Inc. now owns 2,261 shares of the biotechnology company’s stock worth $225,000 after purchasing an additional 883 shares during the period. Trexquant Investment LP bought a new stake in GALAPAGOS NV/S during the third quarter worth approximately $256,000. Moody National Bank Trust Division bought a new stake in GALAPAGOS NV/S during the third quarter worth approximately $394,000. Finally, American National Insurance Co. TX bought a new stake in GALAPAGOS NV/S during the third quarter worth approximately $394,000. 18.08% of the stock is currently owned by institutional investors.
A number of brokerages have recently commented on GLPG. Zacks Investment Research lowered GALAPAGOS NV/S from a “strong-buy” rating to a “hold” rating in a report on Friday, January 4th. BidaskClub upgraded GALAPAGOS NV/S from a “hold” rating to a “buy” rating in a report on Friday, January 11th. ValuEngine upgraded GALAPAGOS NV/S from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 10th. Morgan Stanley upped their price target on GALAPAGOS NV/S from $127.00 to $131.00 and gave the stock an “overweight” rating in a report on Monday, November 5th. Finally, Cantor Fitzgerald started coverage on GALAPAGOS NV/S in a report on Wednesday, December 19th. They set an “overweight” rating and a $130.00 price target for the company. Three research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $122.00.
NASDAQ:GLPG traded down $0.94 during trading hours on Monday, reaching $100.59. The company had a trading volume of 26,525 shares, compared to its average volume of 81,144. GALAPAGOS NV/S has a one year low of $85.00 and a one year high of $122.28. The stock has a market capitalization of $5.20 billion, a price-to-earnings ratio of -38.10 and a beta of 1.70.
About GALAPAGOS NV/S
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Recommended Story: What is the return on assets (ROA) ratio?